(Unaudited)Six Months Ended
(Unaudited)2011201020112010Revenues: License fees
4,853 Sponsored research132—222— Reimbursable research and development costs9671,0951,5711,942Total revenues2,1763,5213,9466,795Operating expenses: Research and development15,52712,88428,24223,135 General and administrative4,7693,3199,0186,246Total operating expenses20,29616,20337,26029,381Loss from operations(18,120)(12,682)(33,314)(22,586)Other income (expense): Interest income98111205180 Interest expense(98)(229)(232)(490) Other income, net613926Total other income (expense)6(105)(18)(284)Net loss
(22,870)Basic and diluted net loss per share
(1.11)Shares used in computing basic and diluted net loss per share 26,68722,55626,24120,568Condensed Consolidated Balance Sheet Data(in thousands)June 30,
2010Cash, cash equivalents and short-term investments
100,454Total stockholders' equity
77,123About Ardea Biosciences, Inc.Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad (RDEA594), our lead product candidate for the chronic management of hyperuricemia in patients with gout, is a once-daily, oral inhibitor of the URAT1 transporter.
|SOURCE Ardea Biosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved